Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.

A A PillaiR MaheshwariR VoraJ P NorvellR FordS ParekhN ChengA PatelN YoungJ R SpiveyO MgbemenaJoel P Wedd

Published in: Alimentary pharmacology & therapeutics (2017)

Our data confirm excellent SVR outcomes and favourable safety and tolerability profiles with ledipasvir/sofosbuvir without ribavirin in post-liver transplant recipients infected with HCV, despite treatment guidelines to use ribavirin.

Keyphrases

hepatitis c virus
human immunodeficiency virus
clinical trial
randomized controlled trial
metabolic syndrome
combination therapy
big data
adipose tissue
hiv infected
hepatitis c virus infection